Wutah dodolan YoY sajrone 12 wulan kepungkur: Candel Therapeutics (CADL)

The TTM year-over-year sales growth rate demonstrates the success of Candel Therapeutics (CADL) innovative viral therapy methods, which create a scientific barrier for competitors. Protected platforms and grants from industry behemoths serve as the foundation, yet high capital expenditure and the risk of trial failure force the company to conduct secondary offerings. The 0.00 mark shows the current state of this metric on this chart.
Candel Therapeutics - rincian analitis lan metrik utama (CADL)

The scale of commercialization for viral immunotherapy in oncology is reflected in the 12-month trailing revenue growth history for Candel Therapeutics (CADL). This indicator measures the percentage deviation of total sales over the last four quarters compared to the same period last year, capturing the market consensus on the growth rates of revenue from insurance payouts and government funds in real-time.